AK

Akanda Corp.

AKANHealthcareNASDAQ

Drug Manufacturers - Specialty & Generic · Last scanned Jul 22, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$258,075
Net Income
-$45.7M
-1014.6% YoY
EBITDA
-$46.0M
-1387.3% YoY
Free Cash Flow
-$5.7M

Scan Results

Daily timeframe
6 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 RSI OversoldRSI 0.7, below 30, stock may be oversold
Jul 14 RSI OversoldRSI 14.8, below 30, stock may be oversold
About Akanda Corp.

Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. At a $4.3M market cap, Akanda Corp. ranks as a micro-cap company within healthcare. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers.

Where AKAN stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, AKAN finished 18.91% below its 150-day moving average ($11.69) and 51.68% below its 200-day moving average ($19.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AKAN overbought or oversold?

At the July 15, 2026 close, AKAN's RSI(14) was 0.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$4.3M
EPS$-13371.10
Beta14.16
52W Change-91.6%
Analysis

Akanda Corp. carries $14.2M in total debt against $504K in cash reserves — debt is roughly 28.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$5.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has been uneven over recent years, ranging from $41K to $258K.

With a beta above 1.5, AKAN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Akanda Corp. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
AKAN: Akanda Corp. Technical Analysis (200-Day MA, RSI, MACD) | Scanance